Sarcoidosis future or investigational therapies: Difference between revisions
mNo edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Sarcoidosis}} | {{Sarcoidosis}} | ||
{{CMG}} {{AE}} | {{CMG}} {{AE}}Roshan Dinparasti Saleh M.D. | ||
==Overview== | ==Overview== | ||
The emergence of biological therapies has increased the therapeutic options available to treat [[sarcoidosis]], with monoclonal anti-TNF agents being the most promising, but their use is still limited by a lack of licensing and costs. | |||
==Future or investigational therapies== | ==Future or investigational therapies== | ||
The emergence of biological therapies has increased the therapeutic options available to treat [[sarcoidosis]], with monoclonal anti-TNF agents being the most promising, but their use is still limited by a lack of licensing and costs. | |||
==References== | ==References== | ||
Latest revision as of 23:24, 14 May 2018
|
Sarcoidosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Sarcoidosis future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Sarcoidosis future or investigational therapies |
|
Risk calculators and risk factors for Sarcoidosis future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Roshan Dinparasti Saleh M.D.
Overview
The emergence of biological therapies has increased the therapeutic options available to treat sarcoidosis, with monoclonal anti-TNF agents being the most promising, but their use is still limited by a lack of licensing and costs.
Future or investigational therapies
The emergence of biological therapies has increased the therapeutic options available to treat sarcoidosis, with monoclonal anti-TNF agents being the most promising, but their use is still limited by a lack of licensing and costs.